Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)

Mansoura University

Status: Completed

Conditions: Small Bowel Obstruction

Treatments: Other: Oral Gastrografin; Other: Nothing per os

Study type: Interventional

Funder types: Other

Identifiers

NCT00738855

oral

follow through

adhesive SBO.

oral gastrografin

in

gastrografin

Details and patient eligibility

About

Mini abstract :

Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups. Eight episodes in eight patients were excluded. Gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .The need for surgery was reduced but statistically insignificant.

Full description

Abstract

Background:

Many published studies have shown that Gastrografin can be used for diagnosis post operative acute small bowel obstruction (ASBO) and assessing the need for surgical intervention .However,the studies have reported conflicting results hence the aim of our study to test this hypothesis.

Patients and methods :

Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups in a double blinded fashion. Eight episodes in eight patients were excluded due to protocol violation. In Gastrografin group,100 ml of the dye administered through a nasogastric tube and complete obstruction has been considered if the contrast failed to reach the colon on the 24-hour film. Patients were operated on only if they developed signs of strangulation or failed to improve within 48 hours.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted to our surgical department by postoperative SBO were considered for inclusion in this trial.

Exclusion criteria

• Age less than 18 years
• Large bowel obstruction
• Recent (within 4 weeks) abdominal surgery
• Ileus
• Cancer peritonitis
• Peritonitis
• Strangulation symptoms and signs
• Obstructed abdominal wall or groin hernia
• Subtotal or total colectomy
• All patients in whom the final diagnosis was not SBO

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

Gastrografin group

Treatment:

Other: Oral Gastrografin

2

Placebo Comparator group

Description:

Control group

Treatment:

Other: Nothing per os